Lorentz A, Müller L, et al.
Journal of gastrointestinal and liver diseases : JGLD. Date of publication 2022 Mar 19;volume 31(1):74-84.
1. J Gastrointestin Liver Dis. 2022 Mar 19;31(1):74-84. doi: 10.15403/jgld-3936.
Probiotics in the Treatment of Inflammatory Bowel Disease in Adulthood: A
Systematic Review.
Lorentz A(1), Müller L(2).
Author information:
(1)Institute of Nutritional Medicine, University of Hohenheim, Stuttgart,
Germany. lorentz@uni-hohenheim.de.
(2)Institute of Nutritional Medicine, University of Hohenheim, Stuttgart,
Germany. muellerleonie@gmx.de.
Erratum in
J Gastrointestin Liver Dis. 2022 Sep 16;31(3):360. doi: 10.15403/jgld-4598.
BACKGROUND AND AIMS: Crohn's disease (CD) and ulcerative colitis (UC) are
inflammatory bowel diseases (IBD) characterized by chronic uncontrolled
inflammation with an increasing prevalence in western countries. Standard
medications are often associated with adverse side effects. Thus, alternative
therapies such as probiotic treatment are of great interest. We aimed to review
the effect of probiotics in IBD patients.
METHODS: A systematic search strategy was carried out in PubMed in June 2021 and
22 studies published from 1997 to 2019 were included; they analyzed the
influence of probiotics in adult IBD patients both in active and inactive stage
of disease.
RESULTS: Probiotic treatment in CD patients had no effect in 6 of 7 studies.
Only in one study a positive effect of an adjunctive probiotic treatment next to
standard treatment in CD patients was reported. In patients with active UC, a
combination of standard treatment with probiotics resulted in improvement of the
disease in 5 of 9 studies. Three of 7 studies among UC patients in remission
demonstrated that probiotic treatment could be as effective as standard
treatment. No clear evidence was found in studies comparing probiotics to
placebo in inactive UC patients with ongoing standard medication.
CONCLUSION: There is no clear evidence of the benefit of probiotic treatment in
CD patients. In contrast, combining standard treatment with probiotics might be
an option to achieve remission in active UC patients.
DOI: 10.15403/jgld-3936
PMID: 35306546 [Indexed for MEDLINE]
Appears in following Topics:
